Phoenix Molecular Designs
Phoenix Molecular Designs specializes in creating precision cancer therapeutics, particularly focusing on RSK inhibitors for various cancers including breast and prostate cancer, with an emphasis on treating triple negative breast cancer.
Services
Phoenix Molecular Designs specializes in designing precise cancer therapeutics targeting RSK, a driver in cancerous tumor growth and metastases. The company focuses on developing novel drugs for at least 14 different types of cancer, including breast and prostate cancer. They emphasize providing precision medicine based on the genetic composition of a person’s tumor to offer targeted treatment options.
Products
Phoenix Molecular Designs develops novel drugs, with its flagship product being the lead candidate PMD-026. PMD-026 is designed to treat triple negative breast cancer (TNBC), a highly aggressive type of breast cancer with limited treatment options beyond chemotherapy. The company focuses on patented RSK inhibitors and companion diagnostics for various cancers, including those in the brain, breast, colon, and prostate.
Clinical Trials
Phoenix Molecular Designs has completed a first-in-human clinical trial with its lead candidate PMD-026 in breast cancer patients. The company successfully completed patient enrollment in the Phase 1/1b Clinical Trial of PMD-026. Their patented cancer compounds aid in streamlining products to market through patient selection using companion diagnostics.
Sector
Phoenix Molecular Designs operates in the biotechnology sector, specifically within the field of cancer therapeutics. The company focuses on designing RSK inhibitors aimed at treating cancerous tumor growth and metastases. Their work includes the development of companion diagnostics for precision medicine targeting the genetic makeup of an individual's tumor.
Research and Development
Phoenix Molecular Designs places a heavy emphasis on research and development, particularly in designing therapeutics targeting the RSK protein. This protein is linked to cancerous tumor growth and metastases. Their R&D efforts have led to the creation of proprietary compounds and therapeutics like the lead candidate PMD-026, aimed at various cancers, including the challenging triple negative breast cancer.